Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Teniposide
- Accession Number
- DB00444 (APRD00649)
- Type
- Small Molecule
- Groups
- Approved
- Description
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. [PubChem]
- Structure
Structure for DB00444 (Teniposide)
- Synonyms
- 4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside)
- Epidophyllotoxin
- Teniposid
- Téniposide
- Teniposido
- Teniposidum
- External IDs
- EPT / PGT / VM-26 / VM26
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Teniposide Injection, solution 10 mg/mL Intravenous WG Critical Care, LLC 2013-04-30 Not applicable US 
Vumon Liquid 10 mg Intravenous Bristol Myers Squibb 1984-12-31 Not applicable Canada 
- International/Other Brands
- Bang Lai (Double-Crane)
- Categories
- Antineoplastic Agents
- Antineoplastic and Immunomodulating Agents
- BCRP/ABCG2 Substrates
- Carbohydrates
- Cardiotoxic antineoplastic agents
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Glucosides
- Glycosides
- Immunosuppressive Agents
- Myelosuppressive Agents
- P-glycoprotein/ABCB1 Substrates
- Podophyllotoxin Derivatives
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- UNII
- 957E6438QA
- CAS number
- 29767-20-2
- Weight
- Average: 656.654
Monoisotopic: 656.1563618 - Chemical Formula
- C32H32O13S
- InChI Key
- NRUKOCRGYNPUPR-QBPJDGROSA-N
- InChI
- InChI=1S/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16-,21+,23+,24-,26+,27+,28+,29+,31+,32-/m0/s1
- IUPAC Name
- (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-(thiophen-2-yl)-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1,3(7),8-trien-12-one
- SMILES
- [H][C@]12COC(=O)[C@]1([H])[C@]([H])(C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@@]2([H])O[C@]1([H])O[C@]2([H])CO[C@]([H])(O[C@@]2([H])[C@]([H])(O)[C@@]1([H])O)C1=CC=CS1
Pharmacology
- Indication
Teniposide is used for the treatment of refractory acute lymphoblastic leukaemia
- Associated Conditions
- Pharmacodynamics
Teniposide is a phase-specific cytotoxic drug, acting in the late S or early G 2 phase of the cell cycle, thus preventing cells from entering mitosis. Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA: protein cross-links.
- Mechanism of action
The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. Teniposide binds to and inhibits DNA topoisomerase II. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.
Target Actions Organism ADNA topoisomerase 2-alpha inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Route of elimination
From 4% to 12% of a dose is excreted in urine as parent drug. Fecal excretion of radioactivity within 72 hours after dosing accounted for 0% to 10% of the dose.
- Half life
5 hours
- Clearance
- 10.3 mL/min/m2
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Teniposide Metabolism Pathway Drug metabolism Teniposide Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Abiraterone The metabolism of Teniposide can be decreased when combined with Abiraterone. Approved Acetyl sulfisoxazole The metabolism of Teniposide can be decreased when combined with Acetyl sulfisoxazole. Approved, Vet Approved Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Teniposide. Approved Acetyldigoxin Acetyldigoxin may decrease the cardiotoxic activities of Teniposide. Experimental Amiodarone The metabolism of Teniposide can be decreased when combined with Amiodarone. Approved, Investigational Amobarbital The serum concentration of Teniposide can be decreased when it is combined with Amobarbital. Approved, Illicit Ancestim The risk or severity of cytotoxicity can be increased when Ancestim is combined with Teniposide. Approved, Investigational, Withdrawn Anthrax immune globulin human The risk or severity of adverse effects can be increased when Teniposide is combined with Anthrax immune globulin human. Approved Apalutamide The serum concentration of Teniposide can be decreased when it is combined with Apalutamide. Approved, Investigational Aprepitant The serum concentration of Teniposide can be increased when it is combined with Aprepitant. Approved, Investigational Armodafinil The metabolism of Teniposide can be decreased when combined with Armodafinil. Approved, Investigational Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Teniposide. Approved, Investigational, Withdrawn Atazanavir The metabolism of Teniposide can be decreased when combined with Atazanavir. Approved, Investigational Atomoxetine The metabolism of Teniposide can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Teniposide is combined with Atorvastatin. Approved Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Teniposide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Teniposide is combined with Bacillus calmette-guerin substrain tice live antigen. Approved Barbexaclone The serum concentration of Teniposide can be decreased when it is combined with Barbexaclone. Experimental Barbital The serum concentration of Teniposide can be decreased when it is combined with Barbital. Illicit BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Teniposide. Investigational Bevacizumab Bevacizumab may increase the cardiotoxic activities of Teniposide. Approved, Investigational Boceprevir The metabolism of Teniposide can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Teniposide can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Teniposide can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Teniposide. Approved Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Teniposide. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Teniposide. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Teniposide. Approved Carbamazepine The metabolism of Teniposide can be increased when combined with Carbamazepine. Approved, Investigational Ceritinib The serum concentration of Teniposide can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Teniposide. Approved, Withdrawn Chloramphenicol The metabolism of Teniposide can be decreased when combined with Chloramphenicol. Approved, Vet Approved Cholecalciferol The metabolism of Teniposide can be decreased when combined with Cholecalciferol. Approved, Nutraceutical Cimetidine The metabolism of Teniposide can be decreased when combined with Cimetidine. Approved, Investigational Citalopram The metabolism of Teniposide can be decreased when combined with Citalopram. Approved Clarithromycin The metabolism of Teniposide can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Teniposide can be decreased when combined with Clemastine. Approved, Investigational Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Teniposide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Clotrimazole The metabolism of Teniposide can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Teniposide is combined with Clozapine. Approved Cobicistat The metabolism of Teniposide can be decreased when combined with Cobicistat. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Teniposide. Approved, Investigational Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Teniposide is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Crizotinib The metabolism of Teniposide can be decreased when combined with Crizotinib. Approved Curcumin The metabolism of Teniposide can be decreased when combined with Curcumin. Approved, Investigational Cyclophosphamide Cyclophosphamide may increase the cardiotoxic activities of Teniposide. Approved, Investigational Cyclosporine The metabolism of Teniposide can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cymarin Cymarin may decrease the cardiotoxic activities of Teniposide. Experimental Dabrafenib The serum concentration of Teniposide can be decreased when it is combined with Dabrafenib. Approved, Investigational Darunavir The metabolism of Teniposide can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Teniposide can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Teniposide can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Teniposide can be decreased when combined with Delavirdine. Approved Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Teniposide. Approved Deslanoside Deslanoside may decrease the cardiotoxic activities of Teniposide. Approved Digitoxin Digitoxin may decrease the cardiotoxic activities of Teniposide. Approved, Investigational Digoxin Digoxin may decrease the cardiotoxic activities of Teniposide. Approved Digoxin Immune Fab (Ovine) Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Teniposide. Approved Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Teniposide. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Teniposide. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Teniposide. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Teniposide. Approved, Investigational Diltiazem The metabolism of Teniposide can be decreased when combined with Diltiazem. Approved, Investigational Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Teniposide. Approved, Investigational Doxycycline The metabolism of Teniposide can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Teniposide can be decreased when combined with Dronedarone. Approved Efavirenz The metabolism of Teniposide can be decreased when combined with Efavirenz. Approved, Investigational Eltrombopag The serum concentration of Teniposide can be increased when it is combined with Eltrombopag. Approved Enzalutamide The serum concentration of Teniposide can be decreased when it is combined with Enzalutamide. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Teniposide. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Teniposide. Approved Erythromycin The metabolism of Teniposide can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Eslicarbazepine acetate The metabolism of Teniposide can be decreased when combined with Eslicarbazepine acetate. Approved Esomeprazole The metabolism of Teniposide can be decreased when combined with Esomeprazole. Approved, Investigational Etravirine The metabolism of Teniposide can be decreased when combined with Etravirine. Approved Fingolimod Teniposide may increase the immunosuppressive activities of Fingolimod. Approved, Investigational Fluconazole The metabolism of Teniposide can be decreased when combined with Fluconazole. Approved, Investigational Fluoxetine The metabolism of Teniposide can be decreased when combined with Fluoxetine. Approved, Vet Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Teniposide. Approved Fluvoxamine The metabolism of Teniposide can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Teniposide can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Teniposide can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Teniposide can be decreased when it is combined with Fosphenytoin. Approved, Investigational Fusidic Acid The serum concentration of Teniposide can be increased when it is combined with Fusidic Acid. Approved, Investigational G17DT The risk or severity of adverse effects can be increased when Teniposide is combined with G17DT. Investigational Gemfibrozil The metabolism of Teniposide can be decreased when combined with Gemfibrozil. Approved GI-5005 The risk or severity of adverse effects can be increased when Teniposide is combined with GI-5005. Investigational Gitoformate Gitoformate may decrease the cardiotoxic activities of Teniposide. Experimental Hepatitis A Vaccine The risk or severity of adverse effects can be increased when Teniposide is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when Teniposide is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Hexobarbital The serum concentration of Teniposide can be decreased when it is combined with Hexobarbital. Approved Human rabies virus immune globulin The risk or severity of adverse effects can be increased when Teniposide is combined with Human rabies virus immune globulin. Approved Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Teniposide. Approved Idelalisib The metabolism of Teniposide can be decreased when combined with Idelalisib. Approved Imatinib The metabolism of Teniposide can be decreased when combined with Imatinib. Approved Indinavir The metabolism of Teniposide can be decreased when combined with Indinavir. Approved INGN 201 The risk or severity of adverse effects can be increased when Teniposide is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Teniposide is combined with INGN 225. Investigational Isavuconazole The serum concentration of Teniposide can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Teniposide can be decreased when combined with Isavuconazonium. Approved, Investigational Isoniazid The metabolism of Teniposide can be decreased when combined with Isoniazid. Approved, Investigational Isradipine The metabolism of Teniposide can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Teniposide can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Teniposide can be increased when it is combined with Ivacaftor. Approved Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Teniposide is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Ketoconazole The metabolism of Teniposide can be decreased when combined with Ketoconazole. Approved, Investigational Lanatoside C Lanatoside C may decrease the cardiotoxic activities of Teniposide. Experimental Leflunomide The risk or severity of adverse effects can be increased when Teniposide is combined with Leflunomide. Approved, Investigational Lipegfilgrastim Teniposide may increase the myelosuppressive activities of Lipegfilgrastim. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Teniposide. Approved, Investigational Lobeglitazone The metabolism of Teniposide can be decreased when combined with Lobeglitazone. Approved, Investigational Lopinavir The metabolism of Teniposide can be decreased when combined with Lopinavir. Approved Lorpiprazole The serum concentration of Teniposide can be increased when it is combined with Lorpiprazole. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Teniposide. Approved, Investigational Luliconazole The serum concentration of Teniposide can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Teniposide can be decreased when it is combined with Lumacaftor. Approved Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Teniposide. Illicit, Investigational, Withdrawn Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Teniposide. Approved, Investigational, Withdrawn Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Teniposide. Experimental Methohexital The serum concentration of Teniposide can be decreased when it is combined with Methohexital. Approved Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Teniposide. Approved Methylphenobarbital The serum concentration of Teniposide can be decreased when it is combined with Methylphenobarbital. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Teniposide. Approved Metildigoxin Metildigoxin may decrease the cardiotoxic activities of Teniposide. Experimental Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Teniposide. Experimental Mifepristone The serum concentration of Teniposide can be increased when it is combined with Mifepristone. Approved, Investigational Mitotane The serum concentration of Teniposide can be decreased when it is combined with Mitotane. Approved Moclobemide The metabolism of Teniposide can be decreased when combined with Moclobemide. Approved, Investigational Modafinil The metabolism of Teniposide can be decreased when combined with Modafinil. Approved, Investigational Natalizumab The risk or severity of adverse effects can be increased when Teniposide is combined with Natalizumab. Approved, Investigational Nefazodone The metabolism of Teniposide can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Teniposide can be decreased when combined with Nelfinavir. Approved Netupitant The serum concentration of Teniposide can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Teniposide can be increased when combined with Nevirapine. Approved Nicardipine The metabolism of Teniposide can be decreased when combined with Nicardipine. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Teniposide. Approved, Investigational Nilotinib The metabolism of Teniposide can be decreased when combined with Nilotinib. Approved, Investigational Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Teniposide. Approved, Investigational Olaparib The metabolism of Teniposide can be decreased when combined with Olaparib. Approved Oleandrin Oleandrin may decrease the cardiotoxic activities of Teniposide. Experimental, Investigational Omeprazole The metabolism of Teniposide can be decreased when combined with Omeprazole. Approved, Investigational, Vet Approved Osimertinib The serum concentration of Teniposide can be increased when it is combined with Osimertinib. Approved Ouabain Ouabain may decrease the cardiotoxic activities of Teniposide. Approved Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Teniposide. Approved, Vet Approved Palbociclib The serum concentration of Teniposide can be increased when it is combined with Palbociclib. Approved, Investigational Pantoprazole The metabolism of Teniposide can be decreased when combined with Pantoprazole. Approved Pentobarbital The serum concentration of Teniposide can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Teniposide. Approved, Investigational, Vet Approved, Withdrawn Peruvoside Peruvoside may decrease the cardiotoxic activities of Teniposide. Experimental Phenobarbital The serum concentration of Teniposide can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenytoin The serum concentration of Teniposide can be decreased when it is combined with Phenytoin. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Teniposide. Approved, Investigational Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Teniposide. Approved Pitolisant The serum concentration of Teniposide can be decreased when it is combined with Pitolisant. Approved, Investigational Posaconazole The metabolism of Teniposide can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Teniposide. Approved Primidone The serum concentration of Teniposide can be decreased when it is combined with Primidone. Approved, Vet Approved Proscillaridin Proscillaridin may decrease the cardiotoxic activities of Teniposide. Experimental Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Teniposide is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rabies virus inactivated antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Teniposide. Approved, Investigational Ranolazine The metabolism of Teniposide can be decreased when combined with Ranolazine. Approved, Investigational Rifabutin The metabolism of Teniposide can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Teniposide can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Teniposide can be increased when combined with Rifapentine. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Teniposide. Approved Rindopepimut The risk or severity of adverse effects can be increased when Teniposide is combined with Rindopepimut. Investigational Roflumilast Roflumilast may increase the immunosuppressive activities of Teniposide. Approved Rolapitant The serum concentration of Teniposide can be increased when it is combined with Rolapitant. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Teniposide. Approved Rotavirus Vaccine The risk or severity of adverse effects can be increased when Teniposide is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Teniposide is combined with Rubella virus vaccine. Approved, Investigational Rucaparib The metabolism of Teniposide can be decreased when combined with Rucaparib. Approved, Investigational Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when Teniposide is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when Teniposide is combined with Salmonella typhi ty21a live antigen. Approved Saquinavir The metabolism of Teniposide can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Teniposide can be decreased when used in combination with Sarilumab. Approved, Investigational Secobarbital The serum concentration of Teniposide can be decreased when it is combined with Secobarbital. Approved, Vet Approved Sertraline The metabolism of Teniposide can be decreased when combined with Sertraline. Approved Sildenafil The metabolism of Teniposide can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Teniposide can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Teniposide can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Teniposide. Approved Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Teniposide. Approved, Investigational SRP 299 The risk or severity of adverse effects can be increased when Teniposide is combined with SRP 299. Investigational St. John's Wort The serum concentration of Teniposide can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Teniposide can be increased when it is combined with Stiripentol. Approved Sulfisoxazole The metabolism of Teniposide can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Tacrolimus Tacrolimus may increase the immunosuppressive activities of Teniposide. Approved, Investigational Tecemotide The risk or severity of adverse effects can be increased when Teniposide is combined with Tecemotide. Investigational Telaprevir The metabolism of Teniposide can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Teniposide can be decreased when combined with Telithromycin. Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Teniposide. Experimental Teriflunomide The serum concentration of Teniposide can be increased when it is combined with Teriflunomide. Approved TG4010 The risk or severity of adverse effects can be increased when Teniposide is combined with TG4010. Investigational Thiamylal The serum concentration of Teniposide can be decreased when it is combined with Thiamylal. Approved, Vet Approved Thiopental The serum concentration of Teniposide can be decreased when it is combined with Thiopental. Approved, Vet Approved Ticlopidine The metabolism of Teniposide can be decreased when combined with Ticlopidine. Approved Tocilizumab The serum concentration of Teniposide can be decreased when it is combined with Tocilizumab. Approved Tofacitinib Teniposide may increase the immunosuppressive activities of Tofacitinib. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Teniposide. Approved Topiramate The metabolism of Teniposide can be decreased when combined with Topiramate. Approved Tranylcypromine The metabolism of Teniposide can be decreased when combined with Tranylcypromine. Approved, Investigational Trastuzumab Trastuzumab may increase the cardiotoxic activities of Teniposide. Approved, Investigational Typhoid Vaccine The risk or severity of adverse effects can be increased when Teniposide is combined with Typhoid Vaccine. Approved Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when Teniposide is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Vemurafenib The serum concentration of Teniposide can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Teniposide can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Teniposide can be decreased when combined with Verapamil. Approved Vincristine Teniposide may increase the neurotoxic activities of Vincristine. Approved, Investigational Voriconazole The metabolism of Teniposide can be decreased when combined with Voriconazole. Approved, Investigational Yellow Fever Vaccine The risk or severity of adverse effects can be increased when Teniposide is combined with Yellow Fever Vaccine. Approved, Investigational Ziprasidone The metabolism of Teniposide can be decreased when combined with Ziprasidone. Approved Zucapsaicin The metabolism of Teniposide can be decreased when combined with Zucapsaicin. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- KEGG Drug
- D02698
- KEGG Compound
- C11153
- PubChem Compound
- 452548
- PubChem Substance
- 46507536
- ChemSpider
- 398606
- ChEMBL
- CHEMBL452231
- Therapeutic Targets Database
- DAP000651
- PharmGKB
- PA451611
- HET
- 9TP
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Teniposide
- ATC Codes
- L01CB02 — Teniposide
- AHFS Codes
- 10:00.00 — Antineoplastic Agents
- PDB Entries
- 4l9q
- MSDS
- Download (46.6 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1, 2 Completed Treatment Malignant Lymphomas 1 2 Completed Treatment Acute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic 1 2 Completed Treatment Malignant Lymphomas 1 2 Recruiting Treatment Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma 1 2 Unknown Status Treatment Leukemias 1 3 Completed Treatment Acute Lymphoblastic Leukaemias (ALL) 1 4 Active Not Recruiting Treatment Acute Lymphoblastic Leukaemias (ALL) 1 4 Completed Treatment Adult Acute Lymphocytic Leukemia 4 4 Unknown Status Treatment Adult Acute Lymphocytic Leukemia 1 Not Available Completed Treatment Bipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder 1 Not Available Unknown Status Treatment Leukemias 1
Pharmacoeconomics
- Manufacturers
- Bristol myers squibb co pharmaceutical research institute
- Packagers
- Bristol-Myers Squibb Co.
- Mead Johnson and Co.
- Dosage forms
Form Route Strength Injection, solution Intravenous 10 mg/mL Liquid Intravenous 10 mg - Prices
Unit description Cost Unit Vumon 10 mg/ml ampul 75.31USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 242-246 °C PhysProp logP 1.24 HANSCH,C ET AL. (1995) - Predicted Properties
Property Value Source Water Solubility 0.0598 mg/mL ALOGPS logP 2.78 ALOGPS logP 2.78 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 9.33 ChemAxon pKa (Strongest Basic) -3.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 12 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 160.83 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 155.61 m3·mol-1 ChemAxon Polarizability 64.84 Å3 ChemAxon Number of Rings 8 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.8166 Blood Brain Barrier - 0.9584 Caco-2 permeable - 0.5728 P-glycoprotein substrate Substrate 0.6638 P-glycoprotein inhibitor I Non-inhibitor 0.8656 P-glycoprotein inhibitor II Non-inhibitor 0.9094 Renal organic cation transporter Non-inhibitor 0.8549 CYP450 2C9 substrate Non-substrate 0.7897 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Substrate 0.5599 CYP450 1A2 substrate Non-inhibitor 0.7516 CYP450 2C9 inhibitor Non-inhibitor 0.5445 CYP450 2D6 inhibitor Non-inhibitor 0.7197 CYP450 2C19 inhibitor Inhibitor 0.7423 CYP450 3A4 inhibitor Inhibitor 0.7677 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.798 Ames test AMES toxic 0.7291 Carcinogenicity Non-carcinogens 0.9303 Biodegradation Not ready biodegradable 0.9254 Rat acute toxicity 2.8354 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9934 hERG inhibition (predictor II) Non-inhibitor 0.8415
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as podophyllotoxins. These are tetralin lignans in which the benzene moiety of the tetralin skeleton is fused to a 1,3-dioxolane and the cyclohexane is fused to a butyrolactone (pyrrolidin-2-one).
- Kingdom
- Organic compounds
- Super Class
- Lignans, neolignans and related compounds
- Class
- Lignan lactones
- Sub Class
- Podophyllotoxins
- Direct Parent
- Podophyllotoxins
- Alternative Parents
- Aryltetralin lignans / Furanonaphthodioxoles / Tetralins / Pyranodioxins / Dimethoxybenzenes / Methoxyphenols / Benzodioxoles / Anisoles / Phenoxy compounds / Alkyl aryl ethers show 16 more
- Substituents
- Podophyllotoxin / 1-aryltetralin lignan / Linear furanonaphthodioxole / Naphthofuran / Methoxyphenol / Pyranodioxin / Tetralin / M-dimethoxybenzene / Dimethoxybenzene / Benzodioxole show 32 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Ubiquitin binding
- Specific Function
- Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
- Gene Name
- TOP2A
- Uniprot ID
- P11388
- Uniprot Name
- DNA topoisomerase 2-alpha
- Molecular Weight
- 174383.88 Da
References
- de Lucio B, Manuel V, Barrera-Rodriguez R: Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha. Cancer Sci. 2005 Nov;96(11):774-83. [PubMed:16271071]
- Uesaka T, Shono T, Kuga D, Suzuki SO, Niiro H, Miyamoto K, Matsumoto K, Mizoguchi M, Ohta M, Iwaki T, Sasaki T: Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J Neurooncol. 2007 Sep;84(2):119-29. Epub 2007 Mar 15. [PubMed:17361331]
- Winnicka K, Bielawski K, Bielawska A: Cardiac glycosides in cancer research and cancer therapy. Acta Pol Pharm. 2006 Mar-Apr;63(2):109-15. [PubMed:17514873]
- Faure P, Madelaine I: [Topoisomerases: therapeutic value]. Ann Pharm Fr. 1996;54(1):40-4. [PubMed:8702194]
- Umanskaya ON, Ioudinkova ES, Razin SV, Bystritskiy AA: Inhibition of DNA topoisomerase II in living cells stimulates illegitimate recombination. Dokl Biochem Biophys. 2005 Nov-Dec;405:423-5. [PubMed:16480143]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Transporter activity
- Specific Function
- Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4...
- Gene Name
- ABCC6
- Uniprot ID
- O95255
- Uniprot Name
- Multidrug resistance-associated protein 6
- Molecular Weight
- 164904.81 Da
References
- Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD: Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. [PubMed:12414644]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44. [PubMed:12649196]
Drug created on June 13, 2005 07:24 / Updated on June 18, 2018 19:05